Valuation: Gilead Sciences, Inc.

Market Cap 182B 157B 149B 135B 253B 17,414B 255B 1,774B 683B 8,830B 682B 667B 28,160B P/E 2026 *
-44.3x
P/E 2027 * 18.2x
Enterprise Value 198B 172B 162B 147B 276B 19,021B 278B 1,938B 746B 9,644B 745B 728B 30,758B EV / Sales 2026 *
6.46x
EV / Sales 2027 * 5.83x
Free-Float
99.88%
Yield 2026 *
2.25%
Yield 2027 * 2.29%
1 day+2.23%
1 week-3.68%
Current month-0.62%
1 month+4.37%
3 months+14.90%
6 months-1.76%
Current year+18.40%
1 week 123.68
Extreme 123.68
125.88
1 month 118.74
Extreme 118.74
130
Current year 100.42
Extreme 100.42
132
1 year 93.42
Extreme 93.42
132
3 years 57.58
Extreme 57.58
132
5 years 52.23
Extreme 52.23
132
10 years 46.23
Extreme 46.23
132
Manager TitleAgeSince
Chief Executive Officer 61 2019-02-28
Director of Finance/CFO 56 2019-10-31
Compliance Officer - 2025-12-17
Director TitleAgeSince
Director/Board Member 58 2016-08-18
Director/Board Member 73 2017-12-31
Director/Board Member 72 2018-05-08
Change 5-day change 1-year change 3-year change Capi.($)
+0.87%-3.68% - - 182B
-0.19%+1.09%+51.85%+97.36% 1,015B
+0.33%-0.71%+50.62%+65.50% 642B
+0.49%+5.73%+20.88%+72.92% 463B
-0.22%+1.98%+36.33%+38.93% 353B
-0.07%-9.26%+15.16%+24.78% 265B
-0.31%+0.61%+2.73%+12.04% 254B
-1.53%-4.46%+36.90%+44.08% 206B
-1.60%-7.71%-20.79%-59.60% 191B
+0.49%-0.23%+30.00%+93.34% 182B
Average -0.11%-3.35%+24.85%+43.26% 396.69B
Weighted average by Cap. -0.16%-2.21%+33.99%+59.53%

Financials

2026 *2027 *
Net sales 30.7B 26.59B 25.15B 22.77B 42.73B 2,945B 43.05B 300B 115B 1,493B 115B 113B 4,762B 32.68B 28.31B 26.77B 24.24B 45.49B 3,135B 45.83B 319B 123B 1,590B 123B 120B 5,070B
Net income -4.27B -3.7B -3.5B -3.17B -5.95B -410B -5.99B -41.78B -16.08B -208B -16.06B -15.7B -663B 10.28B 8.9B 8.42B 7.62B 14.3B 986B 14.41B 100B 38.64B 500B 38.6B 37.74B 1,594B
Net Debt 16.75B 14.5B 13.72B 12.42B 23.3B 1,606B 23.48B 164B 62.97B 814B 62.9B 61.51B 2,597B 9.12B 7.9B 7.47B 6.77B 12.7B 875B 12.79B 89.19B 34.31B 444B 34.27B 33.51B 1,415B
Logo Gilead Sciences, Inc.
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (98.2%): for the treatment of HIV (71.8% of net sales), oncology diseases (11.2%), hepatitis B virus (11.1%), Ebola virus (3.2%) and other (2.7%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV); - other (1.8%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products. Net sales are distributed geographically as follows: the United States (70.9%), Europe (17.2%) and other (11.9%).
Employees
17,000
Date Price Change Volume
26-09-15 125.10 +0.87% 280
26-09-14 €124.02 -0.58% 25
26-09-11 €124.74 +0.86% 0
26-09-10 €123.68 -1.31% 145
26-09-09 €125.32 -0.27% 150
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
146.41USD
Average target price
158.15USD
Spread / Average Target
+8.02%

Quarterly revenue - Rate of surprise

40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!